IndexIQ Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

IndexIQ Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$404K	Sell	15,553 -535	-3%	-$12.7K	0.01%	628
2021 Q4	$328K	Sell	16,088 -1,040	-6%	-$19.9K	0.01%	908
2021 Q3	$330K	Buy	17,128 +1,716	+11%	+$34.2K	0.01%	953
2021 Q2	$342K	Sell	15,412 -174	-1%	-$3.69K	0.01%	928
2021 Q1	$409K	Sell	15,586 -9,348	-37%	-$222K	0.01%	533
2020 Q4	$466K	Buy	24,934 +2,574	+12%	+$48.1K	0.02%	420
2020 Q3	$380K	Buy	22,360 +1,213	+6%	+$23.6K	0.02%	337
2020 Q2	$493K	Sell	21,147 -2,326	-10%	-$33.7K	0.02%	248
2020 Q1	$197K	Buy	+23,473	New	+$198K	0.01%	327

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VLKIM

Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IndexIQ Advisors's VIVO Position: Q1 2022 in Review

IndexIQ Advisors reduced its Meridian Bioscience Inc (VIVO) stake by 3.3% in Q1 2022, selling an estimated $12.7K and leaving 15,553 shares worth $404K. The position accounts for 0.01% of the portfolio, ranked #628.

IndexIQ Advisors first reported a position in VIVO in Q1 2020 and has held it in 9 quarters since. The position peaked at $493K in Q2 2020. 210 funds tracked by Wall St. Rank hold VIVO as of Q1 2022.

IndexIQ Advisors held 15,553 shares of Meridian Bioscience Inc worth $404K as of Q1 2022.
IndexIQ Advisors sold 535 Meridian Bioscience Inc shares in Q1 2022, an estimated $12.7K.
Meridian Bioscience Inc made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #628 holding.
IndexIQ Advisors first reported a position in Meridian Bioscience Inc in Q1 2020 and has held it in 9 quarters since.
IndexIQ Advisors's Meridian Bioscience Inc position peaked at $493K in Q2 2020.
210 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.